Insurers cut back GLP-1 coverage as demand soars: Found study

By A Mystery Man Writer

As demand surges for GLP-1 therapies, insurers are pulling back on coverage, according to new data from obesity care provider Found. | Sarah Jones Simmer, CEO of Found, said that the trends are likely the result of irresponsible prescribing for recreational reasons causing the pendulum to swing "all the way in the other direction," and it's leading to patients who have genuine medical need struggling to access these therapies.

www.usnews.com/dims4/USNEWS/2c0677c/2147483647/thu

Maker of Wegovy, Ozempic showers money on U.S. obesity doctors

Ozempic and Wegovy weight loss drugs are life changers, for those who can afford them

What is Ozempic and why is B.C. cracking down on sales of the drug to Americans?

Stock market today: Live updates

MCT2D 2023 Updates to Coverage for GLP-1 RAs, SGLT2 i's, and

IPN 2023 January by IPN Communications LTD - Issuu

/sites/default/files/styles/opengraph/p

The Rise of GLP-1 Receptor Agonists and Coverage Challenges

Glucagon-Like Peptide 1 (GLP-1) Agonists Market to Reach USD 20.15 Billion During Forecast Period - Digital Journal

The Doctor Prescribed an Obesity Drug. Her Insurer Called It 'Vanity.' - The New York Times

Ontario limiting access to Ozempic to conserve supply for those